IN BRIEF: BioMedica aids discovery
29 Mar 2000
Oxford BioMedica has licensed its LentiVector gene delivery technology to AstraZeneca. The technique allows researchers to deliver a gene to a particular tissue, which helps identify the role played by the gene in diseases. AstraZeneca will use LentiVector in its drug discovery programme.
